Maria E. Arcila

Maria E. Arcila publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Maria E. Arcila sits on this spectrum.

Maria E. Arcila D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Maria E. Arcila sits on this spectrum.

Overview

Best Publications

• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

  Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  2987
  Citations

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  Marco L. Davila;Isabelle Riviere;Xiuyan Wang;Shirley Bartido

  2920
  Citations

• Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

  Helena A. Yu;Maria E. Arcila;Natasha Rekhtman;Camelia S. Sima

  2525
  Citations

• Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

  Donavan T. Cheng;Talia N. Mitchell;Ahmet Zehir;Ronak H. Shah

  2291
  Citations

• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  Neal I. Lindeman;Philip T. Cagle;Dara L. Aisner;Maria E. Arcila

  1623
  Citations

• Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

  Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  1489
  Citations

• Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

  Zhenfeng Zhang;Zhenfeng Zhang;Jae Cheol Lee;Luping Lin;Victor Olivas

  1302
  Citations

• Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

  Paul K. Paik;Maria E. Arcila;Michael Fara;Camelia S. Sima

  765
  Citations

• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  Ken Takezawa;Valentina Pirazzoli;Maria E. Arcila;Caroline A. Nebhan

  750
  Citations

• Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

  Catherine C. Coombs;Ahmet Zehir;Sean M. Devlin;Ashwin Kishtagari

  703
  Citations

• Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation

  Geoffrey R. Oxnard;Maria E. Arcila;Camelia S. Sima;Gregory J. Riely

  698
  Citations

• Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay

  Maria E. Arcila;Geoffrey R. Oxnard;Khedoudja Nafa;Gregory J. Riely

  687
  Citations

• Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

  Lawrence J. Jennings;Maria E. Arcila;Christopher Corless;Suzanne Kamel-Reid;Suzanne Kamel-Reid

  675
  Citations

• ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

  Justin F. Gainor;Anna M. Varghese;Sai-Hong Ignatius Ou;Sheheryar Kabraji

  630
  Citations

• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  Juliann Chmielecki;Jasmine Y Foo;Geoffrey R. Oxnard;Katherine Hutchinson

  612
  Citations

• Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

  Emmet J. Jordan;Hyunjae R. Kim;Maria E. Arcila;David Barron

  585
  Citations

• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer.

  Hiroyuki Yasuda;Eunyoung Park;Cai Hong Yun;Natasha J. Sng

  540
  Citations

• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  Kadoaki Ohashi;Lecia V. Sequist;Maria E. Arcila;Teresa Moran

  508
  Citations

• Cancer therapy shapes the fitness landscape of clonal hematopoiesis

  Kelly L. Bolton;Ryan N. Ptashkin;Teng Gao;Lior Braunstein

  504
  Citations

• Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.

  Wassim Abida;Joshua Armenia;Anuradha Gopalan;Ryan Brennan

  495
  Citations